Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBIRI with FOLFOX and Bevacizumab for Colorectal Liver Metastases
NCT00932438Phase 2Completed
- Sponsor
- University of Louisville
- Start
- Jun 2009
- Primary completion
- Dec 2012
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by University of Louisville. Primary endpoint: Tumor Response at 6 months. Started Jun 2009; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00932438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932438.